Trials / Completed
CompletedNCT03955575
Treatment of Bile Acid Malabsorption With Liraglutide
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Filip Krag Knop · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Comparing the effect of Liraglutide on bile acid malabsorption, with colesevelam
Detailed description
The overall objective of the present study is to provide proof of concept that treatment with the GLP-1 receptor agonist liraglutide is efficacious (as assessed by symptom relief, i.e. response to treatment) and safe (as assessed by adverse effects) in the management of BAM and that it improves bile acid reabsorption (as assessed by SeHCAT) in these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liraglutide 6 MG/ML | Liraglutide as injections. |
| DRUG | Colesevelam | 3 x 625 miligram 2 times a day. |
Timeline
- Start date
- 2019-03-07
- Primary completion
- 2021-03-10
- Completion
- 2022-05-31
- First posted
- 2019-05-20
- Last updated
- 2022-06-03
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03955575. Inclusion in this directory is not an endorsement.